Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
/
Everest Medicines
1952
Everest Medicines
Rising Regulatory And Pricing Pressures Will Erode Margins Despite Progress
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
HK$25.61
172.0% overvalued
intrinsic discount
16 Aug
HK$69.65
Loading
1Y
272.1%
7D
-1.3%
Author's Valuation
HK$25.6
172.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
HK$25.6
172.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-5b
3b
2018
2020
2022
2024
2025
2026
2028
Revenue CN¥2.9b
Earnings CN¥482.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
30.49%
Biotech revenue growth rate
11.77%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.89%
Calculation
CN¥482.50m
Earnings '28
x
19.29x
PE Ratio '28
=
CN¥9.31b
Market Cap '28
CN¥9.31b
Market Cap '28
/
324.35m
No. shares '28
=
CN¥28.69
Share Price '28
CN¥28.69
Share Price '28
Discounted to 2025 @ 6.89% p.a.
=
CN¥23.50
Fair Value '25
CN¥23.50
Fair Value '25
Converted to HKD @ 1.0899 CNY/HKD Exchange Rate
=
HK$25.61
Fair Value '25
